Weighted Average Monthly Premium for Medicare Part D Stand-alone Prescription Drug Plans November 7, 2024 State Indicator
A Current Snapshot of the Medicare Part D Prescription Drug Benefit October 9, 2024 Issue Brief This brief provides an overview of the Medicare Part D prescription drug benefit, including current data on plan availability, enrollment, and spending and financing, and highlights recent changes under the Inflation Reduction Act.
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity November 26, 2024 Blog This policy watch examines the implications of new proposed regulations that would allow Medicare and require Medicaid to cover drugs used to treat obesity, including a relatively new class of highly effective but costly drugs known as GLP-1s.
How Medicare Negotiated Drug Prices Compare to Other Countries December 19, 2024 Issue Brief This analysis finds that Medicare’s negotiated prices for 10 high-expenditure prescription drugs are lower than what private Medicare drug plans had been paying, but still much higher than the prices available in 11 other wealthy nations.. It is available on the Peterson-KFF Health System Tracker.
FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program January 23, 2025 Issue Brief The Centers for Medicare & Medicaid Services (CMS) recently announced the drugs selected for the second round of negotiation for the Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and CMS’s implementation of the program, with a focus on the details that apply for 2027, the second year that negotiated prices will be available under the program.
Medicare Part D Enrollees Without Low-Income Subsidies (LIS) With Drug Spending Above the Catastrophic Threshold January 19, 2024 State Indicator
KFF Prescription Drug Advertisements Poll: January 2025 February 11, 2025 Poll Finding KFF’s January 2025 Prescription Drug Advertisements Poll looks at the public’s experiences with prescription drug advertisements, whether they’ve talked to a doctor about advertised drugs, and how this has influenced the care they receive.
A Look at Changes in Opioid Prescribing Patterns in Medicaid from 2016 to 2019 February 17, 2023 Issue Brief This analysis builds on previous KFF work by using Medicaid claims data for 2016-2019 to explore how prescriptions for opioids used to treat pain and those used to treat OUD or rapidly reverse overdose changed across states and Medicaid enrollee demographic groups over time.
Year in Review: 10 Health Policy Issues for 2023 December 22, 2023 Fact Sheet This fact sheet offers a look back at 10 issues that KFF tracked closely during 2023 in its polling, policy analysis and journalism, including summaries of major findings and news stories.
Skepticism Surrounding ADHD Diagnoses and Medication — The Monitor February 13, 2025 Page This volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.
